claims Tagged Articles
Judge recuses himself from Actos bladder cancer lawsuit
A judge assigned to hear an Actos bladder cancer lawsuit has recused himself from the case, citing a conflict with one of the pharmacies listed as a defendant in the case.
Federal government, Arkansas jointly sue ExxonMobil over tar sands oil spill
The U.S. Justice Department and the State of Arkansas have filed a joint lawsuit against oil giant ExxonMobil for violations to state and federal pollution laws involving its oil spill that flooded a community with highly toxic Canadian tar sands
Four Florida executive face prison time for WellCare Medicaid fraud scheme
A federal jury in Tampa, Florida found four high-ranking officials of a Florida health maintenance organization (HMO) operator guilty of multiple charges, including health care fraud, making false statements relating to health care matters, and making false statements to a
BP will cease most oil spill cleanup work in June
BP is wrapping up its oil-spill cleanup efforts on the Gulf Coast this month, pulling out of Alabama, Florida, Mississippi, and all but 83 miles of Louisiana coast, the company said. The oil giant has staged cleanup operations for more
National Medicare fraud crackdown uncovers $233 million in false billings
A federal crackdown on Medicare fraud in eight cities nationwide has led to charges against 89 individuals, including doctors, nurses, and other licensed medical professionals, for their alleged participation in fraud schemes that resulted in about $233 million in false
Whistleblower exposes fraud; ISTA Pharmaceuticals settles criminal, civil charges for $33.5 million
ISTA Pharmaceuticals Inc., a unit of Bausch+Lomb, has pleaded guilty to several criminal and civil charges for conspiring to introduce a misbranded drug into the market and pay illegal kickbacks to physicians who prescribed the drug for unapproved uses. ISTA’s
C.R. Bard agrees to pay settle whistleblower fraud allegations for $50 million
Medical products manufacturer C.R. Bard has agreed to pay the U.S. nearly $50 million to resolve allegations that it provided illegal financial rewards to customers and physicians for choosing its products to treat prostate cancer – a violation of the
